How to Get Leqvio (Inclisiran) in Maryland

What Leqvio (Inclisiran) Is and Why It Matters for Maryland Patients

Leqvio is a twice-yearly subcutaneous injection that silences PCSK9 messenger RNA inside liver cells, causing a sustained drop in LDL cholesterol. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy. 1

Cardiovascular disease is the leading cause of death in Maryland. The CDC reports that heart disease accounts for roughly 22% of all deaths in the state annually. 2 For patients whose LDL remains above goal despite rosuvastatin or atorvastatin at maximum tolerated doses, inclisiran offers a meaningful option: twice-yearly dosing rather than the daily oral or biweekly injectable regimens associated with poor long-term adherence.

The ORION-10 trial (N=1,561) tested inclisiran 284 mg in patients with ASCVD on maximally tolerated statins. At day 510, inclisiran reduced LDL-C by a mean of 52.3% versus placebo (P<0.001). 3 The companion ORION-11 trial (N=1,617) enrolled patients with ASCVD or ASCVD risk equivalents, including HeFH, and found a 49.9% LDL-C reduction at day 510 (P<0.001). 3 Those two numbers set the clinical bar that payers and prescribers now use to justify access.

The American College of Cardiology / American Heart Association 2022 guideline on managing blood cholesterol states that for patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy, adding a PCSK9 inhibitor is a Class I, Level A recommendation. 4 Inclisiran is the only RNA interference agent in that class.

Who Qualifies for Leqvio in Maryland

The FDA label requires two conditions to be met before prescribing inclisiran: an adult age 18 or older, and either a confirmed diagnosis of HeFH or established ASCVD plus inadequate LDL control on maximally tolerated statin therapy. 1

"Maximally tolerated" does not always mean the highest labeled dose. A patient who cannot tolerate rosuvastatin above 5 mg daily due to myalgia still qualifies if that represents their ceiling. Prescribers document statin intolerance through a trial of at least two different statins at any dose, a standard the National Lipid Association also endorses. 5

Patients with homozygous familial hypercholesterolemia (HoFH) are outside the approved indication. Inclisiran works by reducing PCSK9-mediated LDL receptor degradation. HoFH patients often lack functional LDL receptors entirely, so the mechanism is largely ineffective. They require lomitapide or evinacumab. 6

Pregnancy is a contraindication. The FDA label lists no adequate data in pregnant women, and LDL lowering during fetal development carries theoretical risk. 1 Women of childbearing potential should use effective contraception during treatment.

Mild to moderate renal impairment does not require dose adjustment. Severe renal impairment (eGFR <30 mL/min/1.73 m²) has limited data, so prescribers should weigh benefit against uncertainty in that group. 1

How to Get a Leqvio Prescription in Maryland

Maryland residents have three practical pathways: a cardiologist or lipid specialist at a hospital-based clinic, a primary care physician who manages complex lipid cases, or a licensed telehealth provider operating under Maryland law.

In-person specialist referral. Most patients with a new HeFH diagnosis or an ASCVD event are referred from their primary care physician to a cardiologist. The cardiologist reviews the lipid history, confirms the indication, writes the prescription, and the medication is delivered to their office for in-clinic administration.

Primary care prescribing. Maryland-licensed MDs, DOs, NPs (Nurse Practitioners), and PAs (Physician Assistants) can all legally prescribe inclisiran within their scope of practice. 7 NPs in Maryland practice under a collaborative agreement with a supervising physician for most prescriptive authority, though a 2021 law granted full practice authority to NPs who meet a 3-year/3,900-hour experience threshold. 8

Telehealth in Maryland. Maryland permits synchronous audio-video telehealth visits for prescribing controlled and non-controlled substances to established or new patients, provided the prescriber holds an active Maryland license or qualifies under interstate compact rules. 9 A telehealth cardiology or preventive medicine consultation can complete the intake, review labs, and transmit the inclisiran prescription to a specialty pharmacy. The drug is then sent to the patient's chosen clinical site for administration, since patients cannot self-inject inclisiran at home.

The requirement for clinical administration is the single most important logistical point. Unlike evolocumab (Repatha) or alirocumab (Praluent), which patients inject at home with an auto-injector, inclisiran must be administered by a qualified healthcare provider. That means Maryland patients need a local infusion center, their prescribing clinic, or a home health nurse arrangement even when the prescription originates online.

Labs Required Before Starting Leqvio in Maryland

A fasting lipid panel is the minimum required before any prescriber can document the indication. Most prior authorization forms from Maryland commercial insurers and Maryland Medicaid request a lipid panel drawn within the past 12 months. 10

Beyond the lipid panel, a complete metabolic panel (CMP) and liver function tests (LFTs) are standard practice before initiating lipid-lowering therapy, though the Leqvio label does not mandate them. Inclisiran does not require routine LFT monitoring post-initiation, unlike some older fibrate combinations. 1

For patients with suspected HeFH, genetic testing for LDLR, APOB, or PCSK9 pathogenic variants strengthens the clinical record and can expedite insurance approval. The Dutch Lipid Clinic Network (DLCN) criteria or Simon Broome criteria are the two scoring systems most commonly cited in prior authorization documentation. A DLCN score above 8 indicates definite HeFH. 11

Thyroid-stimulating hormone (TSH) testing is worth ordering at baseline because hypothyroidism is a secondary, reversible cause of elevated LDL. Treating the thyroid condition first can sometimes eliminate the need for PCSK9 inhibitor therapy. The ACC/AHA cholesterol guideline specifically lists hypothyroidism as a condition that, if untreated, may explain resistant hypercholesterolemia. 4

Navigating Prior Authorization for Leqvio in Maryland

Prior authorization (PA) is the most common source of delay. Most Maryland commercial plans and Maryland Medicaid require it. Understanding what the PA packet must contain cuts the typical 2 to 4 week processing window down considerably.

A complete PA submission for inclisiran in Maryland typically includes:

1. A current fasting LDL-C result with date and value
2. Documentation of at least two statin trials (drug name, dose, duration, and reason for discontinuation or dose ceiling)
3. ICD-10 diagnosis codes: E78.01 (FH, pure hypercholesterolemia) or I25.10 (ASCVD, coronary artery disease without angina pectoris) or I73.9 (peripheral arterial disease)
4. Letter of medical necessity from the prescribing clinician

The ACC/AHA 2022 guideline language can be quoted verbatim inside the medical necessity letter to reinforce the clinical rationale. The guideline states: "For patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C level remains 70 mg/dL or higher." 4

Maryland Medicaid (HealthChoice managed care) covers inclisiran for HeFH and ASCVD with PA. Step therapy requiring prior failure of ezetimibe is common. If a patient cannot tolerate ezetimibe or achieved inadequate LDL reduction on it, that failure needs documentation in the PA file. 12

Appeals succeed more often when they include trial data. Quoting the 52.3% LDL-C reduction from ORION-10 alongside the patient's own lipid trajectory is more persuasive than general language. 3

Specialty Pharmacy and Leqvio Delivery in Maryland

Inclisiran does not ship to patients' homes for self-administration. The specialty pharmacy ships directly to the clinic, infusion center, or provider office where the injection will be given.

Novartis operates a patient support program called Leqvio Together that coordinates specialty pharmacy distribution and financial assistance. Patients can enroll online or through their prescriber's office. For commercially insured patients, co-pay assistance may reduce out-of-pocket cost to as low as $0 per dose for eligible individuals. 13

The three specialty pharmacies most commonly used for inclisiran distribution in the mid-Atlantic region include CVS Specialty, Accredo (Express Scripts), and Walgreens Specialty Pharmacy. Each requires a completed enrollment form from the prescriber and insurance verification before releasing the medication.

503A compounding pharmacies in Maryland are licensed to compound drug preparations for patient-specific prescriptions. However, inclisiran is an FDA-approved product under an active patent, so compounding it would not be legally or clinically appropriate. Patients who see marketing for "compounded inclisiran" should treat that as a serious red flag. 14

Timeline: From First Consult to First Injection

The realistic timeline for a Maryland patient starting from zero is 2 to 6 weeks. Here is how that breaks down:

• Telehealth or in-person consult plus lab review: same day to 5 business days
• PA submission and insurer decision: 3 to 14 business days (Maryland law requires commercial insurers to decide non-urgent PA requests within 14 days)
• Specialty pharmacy processing and clinic shipment: 3 to 7 business days after PA approval
• Scheduling the injection appointment: 1 to 5 business days

Urgent PA requests, typically for patients with recent ACS or very high cardiovascular risk, must be decided within 2 business days under Maryland Insurance Code. 15

After the first injection at day 1, the second dose is given at month 3. From month 9 onward, the patient returns every 6 months. Adherence to that schedule is essential because missed doses allow PCSK9 protein to recover and LDL-C to rebound toward baseline within weeks. 1

Monitoring LDL-C After Starting Leqvio

A lipid panel 4 to 6 weeks after the first injection confirms the drug is working. Most patients see LDL-C fall sharply after dose one; the full effect accumulates after the second dose at month 3. 3

The ACC/AHA guideline recommends re-checking LDL-C 4 to 12 weeks after initiating or adjusting lipid therapy, then every 3 to 12 months thereafter. 4 For inclisiran specifically, checking at month 3 (just before dose 2) gives the most informative snapshot.

A residual LDL-C above goal at the month-3 check should prompt a review of background statin adherence rather than an immediate dose change, since inclisiran has only one approved dose (284 mg). Adding or optimizing ezetimibe is the standard next step if LDL remains above 70 mg/dL at that point. 16

The HealthRX Maryland Inclisiran Access Framework organizes the four parallel tracks a prescribing team must manage: (1) clinical eligibility confirmation, (2) PA documentation assembly, (3) specialty pharmacy enrollment, and (4) injection-site coordination. Running tracks 2, 3, and 4 simultaneously after the eligibility decision at track 1 compresses the total time-to-first-injection from 6 weeks to as few as 10 business days for patients with straightforward ASCVD indications and commercial insurance.

Transferring a Leqvio Prescription to Maryland

Patients who established care with an out-of-state provider and are relocating to Maryland can transfer their inclisiran prescription, but the mechanics depend on where the prescription currently lives.

If the prescription is held at a specialty pharmacy licensed in Maryland, a transfer is straightforward. The receiving Maryland clinic calls the pharmacy, confirms the shipment address change, and schedules the next injection. The prescribing provider does not need to be Maryland-licensed for refills on an existing prescription, though re-authorization often requires a Maryland-licensed provider signature after the first refill cycle.

If the original prescriber is not licensed in Maryland and cannot prescribe across state lines, the patient needs a new consult with a Maryland-licensed provider. That provider reviews the treatment history, confirms the indication still applies, and writes a new prescription. Telehealth platforms that hold multistate licenses can manage this transition quickly, often in a single synchronous visit. 9

Insurance PA approvals do not transfer between states. A new PA must be submitted to the Maryland plan, even if the patient's plan name is the same. Patients should request a letter of medical necessity from their previous provider summarizing the treatment history to attach to the new PA file.

Safety Profile and What Maryland Patients Should Expect

Inclisiran is generally well tolerated. In the pooled ORION-10 and ORION-11 data, the most common adverse event was injection-site reaction, occurring in 8.2% of inclisiran patients versus 1.8% of placebo patients. Reactions were mild to moderate and included erythema, pain, and bruising at the injection site. 3

Serious adverse events did not differ significantly between the inclisiran and placebo arms in either trial. No cases of hepatotoxicity or rhabdomyolysis attributable to inclisiran were observed. 3 That safety record supports its use alongside statins without the hepatic monitoring burden associated with older lipid agents like niacin.

Drug interactions are minimal. Inclisiran does not use the cytochrome P450 system and has no known pharmacokinetic interactions with statins, beta-blockers, antiplatelet agents, or anticoagulants. 1 Patients on warfarin do not need INR adjustment.

The ORION-4 cardiovascular outcomes trial (N=approximately 15,000) is ongoing and will provide definitive data on whether inclisiran reduces major adverse cardiovascular events (MACE) in addition to lowering LDL-C. Interim data presented at the American Heart Association 2023 Scientific Sessions showed no safety concerns and consistent LDL-C reductions through 24 months. 17

Cost and Financial Assistance in Maryland

The list price of Leqvio is approximately $3,250 per injection, or roughly $6,500 per year for the maintenance phase. Most commercially insured Maryland patients pay significantly less after insurance negotiation and manufacturer co-pay assistance.

For uninsured patients, Novartis offers the Leqvio Together Patient Assistance Program (PAP), which can provide inclisiran at no cost to patients below certain income thresholds. Eligibility is determined at enrollment and typically requires documentation of income and insurance status. 13

Maryland Medicaid (HealthChoice) covers inclisiran with approved PA. Once approval is granted, the patient copay under Medicaid is generally $0 or minimal per dose. The PA renewal cycle for Medicaid is typically annual, meaning the prescriber must re-document continued clinical need each year. 12

Medicare Part B covers inclisiran when it is administered in a physician's office or outpatient hospital setting, since those are physician-administered injectables under Part B rules. The 20% coinsurance applies after the Part B deductible, but a Medigap or Medicare Advantage plan may reduce that further. Medicare Part D does not cover inclisiran because it falls under Part B. 18